A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Trial Profile

A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORATORIO; ORCHESTRA
  • Sponsors Roche
  • Most Recent Events

    • 27 Jun 2017 Results of exploratory analysis, presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results (n=699) of post hoc exploratory analysis investigating novel endpoint (No evidence of progression or active disease) in PPMS patients, presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results of exploratory analysis evaluating the risk of being restricted to wheelchair, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top